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Abstract Primary loss and dysfunction of astrocytes may
trigger demyelination, as seen in neuromyelitis optica, an
inﬂammatory disease of the central nervous system. In
most patients affected by this disease, injury to astrocytes is
initiated by the action of autoantibodies targeting aquaporin
4 (AQP-4), a water channel on astrocytes. We show here
that damage of astrocytes and subsequent demyelination
can also occur in the absence of autoantibody-mediated
mechanisms. Following injection of lipopolysaccharide into
the white matter initial microglia activation is followed by a
functional disturbance of astrocytes, mainly reﬂected by
retraction of astrocytic foot processes at the glia limitans
and loss of AQP-4 and connexins, which are involved
in the formation of gap junctions between astrocytes
and oligodendrocytes. Demyelination and oligodendrocyte
degeneration in this model follows astrocyte pathology.
Similar structural abnormalities were also seen in a subset
of active lesions in multiple sclerosis. Our studies suggest
that astrocyte injury may be an important early step in the
cascade of lesion formation in brain inﬂammation.
Keywords Brain inﬂammation   Multiple sclerosis  
Astrocytes   Demyelination   Neuromyelitis optica
Introduction
Tissue injury in inﬂammatory demyelinating diseases, such
as multiple sclerosis (MS), is generally believed to be
induced by primarily targeting myelin sheaths and/or
oligodendrocytes [29]. However, demyelinating diseases,
such as neuromyelitis optica (NMO) reveal that a direct
targeting of myelin or oligodendrocytes is not essential. In
NMO, speciﬁc autoantibodies are directed against the
astrocytic antigen aquaporin 4 (AQP-4) [20, 21] and these
antibodies can initiate tissue injury in the central nervous
system when they reach their target in animals with T-cell-
mediated brain inﬂammation [6, 7]. In this experimental
paradigm [7], as well as in patients with NMO [34], initial
destruction of astrocytes is followed by oligodendrocyte
degeneration and primary demyelination. These studies
indicate that oligodendrocyte injury and demyelination
may in some instances be secondary consequences of
astrocyte dysfunction or degeneration.
Recently, a new model of spinal cord demyelination has
been introduced, resulting from the focal injection of
lipopolysaccharide (LPS) into the spinal white matter [11].
Using this model, it was suggested that microglia, activated
through mechanisms of innate immunity produce toxic
molecules which affect myelin sheaths and oligodendro-
cytes and thereby induce primary demyelination with
partial axonal preservation [11, 26]. However, local
microglial activation is an early response to LPS injection
[26], but demyelination only starts 5–6 days later. This
time lag between microglial activation and the onset of
demyelination argues against a direct toxicity of products
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DOI 10.1007/s00401-010-0704-zof activated microglia in the induction of demyelination. In
light of the new ﬁndings in NMO and its experimental
models, we have analyzed the astrocytic response to LPS
both in vitro and in vivo. Our results show that structural
and functional changes in astrocytes precede demyelination
in a similar way as seen in experimental NMO lesions
raising the possibility that the astrocytes are causally
involved in the demyelination. We also provide evidence
that astrocyte dysfunction may be involved in the patho-
genesis of a subset of active MS lesions.
Materials and methods
Experimental design
Astrocyte pathology was analyzed in four different models
of brain inﬂammation in rats (Table 1). T-cell-mediated
inﬂammation was induced by passive transfer of myelin
basic protein (MBP) reactive encephalitogenic T-cell lines.
Speciﬁc targeting of astrocytes was obtained by co-transfer
of human AQP-4 autoantibody containing immunoglobu-
lins into animals with T-cell-mediated autoimmune
encephalomyelitis (EAE). For controls, demyelination and
oligodendrocyte destruction was induced in a similar way
with co-transfer EAE, using monoclonal antibodies against
myelin oligodendrocyte glycoprotein (MOG). In another
model, inﬂammatory demyelination was triggered by
innate immunity induced by focal injection of LPS into the
spinal cord. Finally, we analyzed astrocyte pathology in
different active MS lesions from patients with acute,
relapsing and progressive MS.
T-cell-mediated EAE
The MBP-speciﬁc T cells used in this study were derived
from Lewis rats according to the standard protocols [5].
The Lewis rats were intraperitoneally injected with
1 9 10
5 activated MBP-speciﬁc T cells or with saline
(controls). Afterwards, the rats were monitored daily for
evidence of weight loss or clinical symptoms of EAE. 3, 6,
9, 12 and 15 days after the induction of EAE, the animals
were killed with an overdose of CO2, and perfused tran-
scardially with 4% paraformaldehyde (PFA) in 0.1 M
phosphate buffered saline (PBS, pH 7.4). The spinal cords
were dissected-free, post-ﬁxed overnight in 4% PFA,
washed with PBS and embedded in parafﬁn.
Co-transfer of encephalitogenic T cells with speciﬁc
autoantibodies
Lewis rats challenged with MBP-speciﬁc T cells, as descri-
bed above received 10 mg human immunoglobulin from
NMO patients or alternatively 10 mg normal human IgG
(Subcuvia
 [7]). Another set of animals with T-cell-medi-
ated EAE received 1 mg of the monoclonal antibody Z12,
directed against the conformational demyelinating epitope
of MOG as described in detail before [23, 31]. Antibodies
Table 1 Characterization of the experimental models and of the MS tissues used
Experimental models/MS tissue Description No. of animals/cases No. of lesions
T-cell EAE T-cell inﬂammation, macrophage activation, edema 3 per time point 108
T-cell EAE ?MOG Ab T-cell inﬂammation, macrophage activation, blood brain
barrier damage, demyelination (antibody ? complement
deposition)
53 0
T-cell EAE ?NMO Ab T-cell inﬂammation, macrophage activation, blood brain
barrier damage, primary astrocytic destruction
(antibody ? complement deposition) (secondary
demyelination)
42 4
Active EAE ?NMO Ab As T-cell EAE ? NMO antibodies, but protracted active
disease and blood brain barrier damage
31 5
LPS Active phase of inﬂammation (granulocytes, few T cells)
followed by microglia activation, macrophage recruitment
and demyelination
3 per time point 42
Saline Transient mild acute inﬂammation (granulocytes) 6 12
MS pattern III Inﬂammatory demyelination, axonal injury, hypoxia-like tissue
injury, mitochondrial damage
62 1
MS pattern II Inﬂammatory demyelination, axonal injury, deposition of
immunoglobulin ? activated complement
21 4
Progressive MS (slowly expanding) Moderate inﬂammation, slowly progressive demyelination,
axonal injury, T cells ? macrophages/microglia
51 1
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123were injected systemically at day 4 after T-cell transfer,
when T-cell-mediated inﬂammation in the central nervous
system isinitiated. Animals were killed1 dayafter antibody
transfer, the brains and spinal cord were dissected and rou-
tinely embedded in parafﬁn. To study later time points in
lesiondevelopment,Lewisratswereactivelysensitizedwith
100 lg of MBP in complete Freund’s adjuvant at the base
of the tail. At the onset of clinical disease (day 10 after
immunization), the animals received an intraperitoneal
injection of NMO IgG or subcuvia. This was repeated 24 h
later. Analysis of lesions in the central nervous system was
performed on day 12 after immunization.
The LPS model
LPS-mediated lesions were induced in rat spinal cord as
described in detail by Felts et al. [11]. Under isoﬂurane
anesthesia, a quarter laminectomy was performed at the
T12 vertebral level and a small hole was made in the
dura. A drawn glass micropipette of an external tip
diameter of 25 lm was then inserted into the dorsal
funiculus and 0.5 ll of LPS (100 ng/ll in saline) was
injected at two adjacent sites, longitudinally 1 mm apart,
at depths of 0.7 and 0.4 mm (2 ll in total). LPS from
Salmonella abortus equi (Sigma, Poole, UK) was used
without further puriﬁcation. Control animals received
injections of saline alone. The injection site was marked
by placing a small amount of sterile powered charcoal on
the adjacent dura.
At different time points after the injections (8 h and 1, 3,
5, 8, 12 and 15 days), the animals were anesthetized with
isoﬂurane and were then perfused transcardially with 4%
PFA in 0.15 M PBS. The spinal cord was dissected-free
and tissue blocks from the injection site as well as from a
region 1 cm rostral and caudal to the injection site were
embedded in parafﬁn.
All animal tissues used in this study were retrieved from
the archives of the Center for Brain Research and the
respective studies have been published earlier [7, 26, 23].
Human autopsy tissue
This study was performed on autopsy brains of MS patients
and control cases from parafﬁn blocks archived in the
Center of Brain Research, Medical University of Vienna,
Austria (Table 1). Hemispheric or double hemispheric
sections of these autopsy brains were characterized and
classiﬁed to identify acute pattern II, pattern III [26],
slowly expanding lesions of progressive MS, and chronic
inactive lesions [12]. As a control, we included autopsy
tissues from eight patients without neurological disease and
without any CNS lesions.
Immunohistochemistry
Immunohistochemical investigations were performed on
3–5-lm thick parafﬁn sections of both human and rat
material. Sections were de-parafﬁnized twice with xylol
substitute (XEM) (Fluka analytical, Germany) for 20 min
each, rinsed twice in 96% EtOH, treated with hydrogen
peroxide in methanol for 30 min to block endogenous
peroxidase, rehydrated in a descending series of EtOH
(96[70[50[30%) and further incubated for 1 h in
phosphate buffered saline containing 10% fetal calf serum
(PBS/CSF) to block non-speciﬁc antibody binding. Antigen
retrieval was performed by heating the sections for 60–
90 min in EDTA (1 mM EDTA, 10 mM Tris, pH 8.5 or 9)
or 0.1 mM citrate buffer (pH 6) in a household food stea-
mer device. The primary antibodies (listed in Table 2)
were applied overnight in PBS/FCS. Afterwards, the slides
were washed 3–4 times in PBS. Then, the slides were
incubated with biotinylated secondary antibodies (sheep
anti-mouse, donkey anti-rabbit, donkey anti-goat; all from
Amersham or Jackson Immuno Research) for 1 h at room
temperature. After washing 3–4 times in PBS, the sections
were treated with avidin peroxidase (diluted 1:100 in 10%
FCS/PBS), and incubated for 1 h at room temperature. For
visualization of the bound antibodies, diaminobenzidine
was used as chromogen as described previously [18].
Confocal laser microscopy
Areas of collagen IV (col IV) deposition and of loss of
astrocytic markers in the EAE and LPS models were
analyzed in serial sections. Fluorescence immunohisto-
chemistry was performed on 3–5-lm thick parafﬁn sections
of both human and rat as described earlier with few mod-
iﬁcations. The sections were deparafﬁnized as described
above, treated with hydrogen peroxide in methanol to block
endogenous peroxidase, and incubated for 20 min in
DAKO diluent to block nonspeciﬁc antibody reactions. For
confocal ﬂuorescent double labeling, glial ﬁbrillary acidic
protein (GFAP) immunoreactivity was visualized using
either a mouse monoclonal or a rabbit polyclonal antibody.
As second marker, we applied mouse monoclonal a-col IV,
anti-a-dystroglycan antibodies, polyclonal a-connexin 43,
or a-AQP-4 antibodies.
The next day, slides were washed twice with PBS.
Then, either ﬂuorochrome-conjugated or biotinylated sec-
ondary antibodies were applied simultaneously for 1 h at
room temperature. When the secondary antibodies were
biotinylated, the labeling was ﬁnished by application of
streptavidin Cy2/Cy3 complexes (Jackson ImmunoResearch,
1:75)for1 hatroomtemperatureinthedark.Theslideswere
mounted with cover slips using Geltol/Gellate. Once slides
weredried(after24 hat4C),theywereanalyzedbyconfocal
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123microscopy. A Leica TCS SP5 LASAF microscope (Leica
microsystems, CMS-GmbH, Germany) was used, equipped
with an argon-ion laser (488 nm excitation) and two HeNe
lasers (543 and 633 nm excitations). Fluorescence signals
were collected simultaneously in the green (Cy2) and red
(Cy3) channels.
Quantitative analysis
Quantitative analysis of demyelination, density of GFAP-
reactive astrocytes and of the expression of astrocytic
antigens within spinal cord cross-sections was performed
on sections stained with LFB or immunocytochemistry,
respectively. Sections were overlaid with a morphometric
grid and the area of myelin loss and loss of astrocytic
antigens was manually determined by counting the grid
points over the respective areas. In addition, we determined
the area of extracellular collagen IV (col IV) deposits
within the CNS parenchyma as well as the number of
astrocytes with cytoplasmic expression of col IV, and the
number of blood vessels with split basal laminae. Areas of
col IV deposition and of loss of astrocytic markers in the
EAEandLPSmodelswereanalyzedinserialsections,using
amicroscopicﬁeldof1 mm
2.Allvaluesareexpressedascell
counts and/or area per mm
2.
Characterization of LPS effects on microglial cells
and astrocytes
Production of mixed glial cultures as a source of microglia
and astrocytes
0-24-h-old Lewis rats were killed and their brains dissected
and transferred to RPMI 1640/10% fetal calf serum (FCS).
After stripping of the meninges, the brains were mechan-
ically dissociated by gentle pipetting. The resulting single
cell suspensions were cultured for 5–7 days in poly-L-
lysine-coated culture ﬂasks, using RPMI1650/10% FCS,
Table 2 Antibodies used for immunostaining
Primary antibody Target Dilution Pre-treatment Secondary
antibody
Dilution CuSO4
enhancement
Immunohistochemistry
a-GFAP (Neomarker) Glial ﬁbrillary acidic
protein
1:3,000 EDTA
pH = 8.5, 60 min
Bio-a-rabbit 1: 2,000 -
a-AQP-4 (Sigma) Aquaporin 4 1:250 None Bio-a-rabbit 1:2,000 -
a-Col IV (Abcam) Collagen IV Ready to use EDTA
pH = 8.5, 60 min
Bio-a-mouse 1:500 -
a-Cx30 (Invitrogen) Connexin 30 1: 5,000 EDTA
pH = 9.0, 60 min
Bio-a-rabbit 1:2,000 1
a-Cx43 (Invitrogen) Connexin 43 1:5,000 EDTA
pH = 9.0, 60 min
Bio-a-rabbit 1:2,000 1
a-C9neo (S.Piddelsden) Complement factor 9 1: 2,000 Protease
(0.005%)
Bio-a-rabbit 1:2,000 -
a-ADG (Hycult Biotech) a-Dystroglycan 1:500 EDTA
pH = 9.0, 60 min
Bio-a-mouse 1:5,000 -
Confocal laser microscopy
a-CNPase (Afﬁnity) 2030-Cyclic nucleotide
30phosphodiesterase
1:500 EDTA
pH = 8.5, 60 min
Bio-a-mouse 1:500
a-Col IV (Abcam) Collagen IV Ready to use Protease
(0.005%)
Bio-a-mouse 1:500
a-GFAP (Neomarker) Glial ﬁbrillary acidic
protein
1:100 EDTA
pH = 8.5, 60 min
Cy2-a-mouse 1:200
a-AQP-4 (Sigma) Aquaporin 4 1:100 None Bio-a-rabbit 1:200
a-Cx43 (Invitrogen) Connexin 43 1:2,000 EDTA
pH = 9.0, 60 min
Bio-a-rabbit 1:200
a-Cx30 (Invitrogen) Connexin 30 1: 2,000 EDTA
pH = 9.0, 60 min
Bio-a-rabbit 1:200
a-DG (2.08) (Hycult Biotech) a-Dystroglycan 1:250 EDTA
pH = 9.0, 60 min
Bio-a-mouse 1:500
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123changing the medium every other day. After this time per-
iod, the mixed glial cell cultures consisted of a monolayer of
astrocytes and ﬁbroblasts. On top of this monolayer, loosely
adherent, ramiﬁed microglial cells and glial progenitor cells
were found.
Microglia cultures
Conﬂuent mixed glial cultures were agitated for 12–15 h
(180 rpm,37C).Thesupernatantwascentrifuged(1,400 rpm,
RT). Afterwards, the cell pellet was re-suspended in RPMI
10% FBS, seeded into uncoated Petri dishes and incubated
for 10 min at 37C, 5% CO2. During this incubation period,
only microglial cells became adherent and stuck to the ﬂoor
of the Petri dish, while other contaminating cells—mostly
glial progenitor cells—remained in the supernatant. The
supernatant was removed and the adherent microglial cells
werewashed2–3timeswithPBSatroomtemperature.These
microglial cultures had a purity of *99%.
Astrocyte-enriched cultures
Conﬂuent mixed glial cultures were agitated for 12–15 h
(180 rpm, 37C). Then, the supernatant was discarded, and
the ﬁrmly adherent cells (mostly astrocytes and ﬁbroblasts)
were rinsed with PBS, trypsinized, re-seeded onto poly-L-
lysine-coated cover slips, and cultured for an additional
1–2 days in RPMI 1640/10% FCS prior to their treatment.
About 75% of all cells in these cultures were astrocytes-
based on GFAP staining.
Stimulation of astrocyte-enriched cultures
For the treatment, each cover slip was transferred to a
separate well of a 12-well-plate and inverted. Small dots
of parafﬁn served as spacers between the cell layer of the
cover slip and the bottom of the 12-well-plate. The
astrocytes growing on the cover slip were either left
untreated as a control (1), received LPS (100 ng/ml) for
12 h (2), or were co-cultured with microglia cells growing
on the bottom of the plate (1:1 ratio of astro-
cytes:microglia cells) in the absence (3) or presence (4) of
LPS (100 ng/ml) for 12 h. Afterwards, the cover slips
were washed twice with PBS and used for immunocyto-
chemical analysis.
Immunocytochemical analysis
The differentially treated cells were ﬁxed with 4% PFA
for 15 min (room temperature), washed with 0.05 M
Tris-buffered saline (TBS) (pH 7.4) and permeabilized
with TBS containing 0.5% Triton, 5% bovine serum
albumin (BSA, Sigma) and 5% donkey serum (Sigma)
for 30 min at room temperature. The cells were then
washed twice with TBS and incubated overnight at 4C
with commercial rabbit anti-AQP-4 antibody and mouse
anti-GFAP antibody (both diluted 1:100 in TBS/1%
donkey serum). Afterwards, the cells were washed three
times with TBS and incubated for 1 h at room temper-
ature with donkey anti-rabbit Cy3 (Jackson Immuno
Research Laboratories, West Grove, PA, USA) to visu-
alize AQP-4 (red) and donkey anti-mouse Cy2 (Jackson
Immuno Research Laboratories) to identify astrocytic
GFAP (green) (both diluted 1:100 in TBS/1% donkey
serum). The cells were washed with TBS and mounted
with gallate/geltol.
Statistical analysis
Quantitative data were analyzed by statistical evaluation
using non-parametric tests. Descriptive analysis included
mean values and standard error. Owing to sample size and
variability of the data, we used non-parametric group tests
(Kruskal–Wallis). SPSS 14.0 statistical software system
(SPSS Inc., Chicago) was used for calculations.
Results
Astrocyte pathology in T-cell-mediated autoimmune
encephalomyelitis ampliﬁed by NMO patient-derived
circulating AQP-4 antibodies
As described before [7] profound loss of AQP-4 and
astrocyte damage is the earliest pathological alteration in
the lesions in the central nervous system of animals with
T-cell-mediated EAE, which received additional systemic
injections of AQP-4 antibody containing immunoglobulin
from patients with NMO (Table 1). One day after anti-
body injection, a profound loss of AQP-4 (Fig. 1b) and
GFAP was seen (Fig. 1c) in the absence of demyelination
(Fig. 1a). This was associated with a major disturbance of
the perivascular glia limitans, as seen in sections stained
for a-dystroglycan (ADG) (Fig. 1d), while the vascular
basement membranes only showed some splitting in the
area of inﬂammation (Fig. 1n). Astrocyte pathology in
these lesions was associated with profound immunoglob-
ulin and complement deposition (Fig. 1h). Three days
after injection of AQP-4 antibody containing immuno-
globulin in animals with actively induced EAE similar
alterations of astrocytes were present (Fig. 1f–h), but at
this time point demyelination was observed within the
lesions. These data show that in the experimental model
Acta Neuropathol (2010) 120:223–236 227
123for NMO, where the speciﬁc antibody response is directed
against the astrocytic antigen AQP-4, demyelination fol-
lows astrocyte injury. Comparable astrocyte alterations and
demyelination were absent in rats with T-cell-mediated
EAE, which received control immunoglobulin (Table 3;
Fig. 1i–l, o–p).
As an additional control, we used spinal cord sections of
animals, in which EAE has been induced with MBP-spe-
ciﬁc T cells and demyelinating antibodies directed against
MOG. In these animals, profound perivascular demyelin-
ation was already present 24 h after the antibody injection.
However, no astrocyte pathology, comparable to that seen
in the experimental NMO model, was present (Fig. 1q–s).
Early loss of AQP-4 in astrocytes in the LPS model
Focalinjectionofsalineintothespinalcordwhitematterdid
notinducedemyelinationorastrocyteinjury(Fig. 2a–d). By
studying the time course of lesion development in the LPS
model, we found loss of AQP-4 immunoreactivity at the
injection site already on the ﬁrst day after LPS injection,
and the extent of AQP-4 loss increased with time (Table 3;
Fig. 2e–l). In the early stages after LPS injection GFAP-
positive astrocytes still appeared normal (Figs. 2g, 3),
but retraction of astrocytic processes was already seen
(Figs. 2a, 3). The reduction in astrocyte numbers was
observed at later stages after LPS injection (Fig. 3k).
Fig. 1 Astrocyte pathology and demyelination in different experi-
mental models of autoimmune encephalomyelitis: immunocyto-
chemistry for the different markers was performed on serial sections
of lesions. T-cell-mediated EAE with co-transfer of human immuno-
globulin containing aquaporin 4 antibody. 24 h after antibody transfer,
thereisnodemyelination(Luxolfastblue staininga),lossofaquaporin
4( b), GFAP (c) and a-dystroglycan (d) in the lesions. 72 h after
antibodytransfer,thelossofaquaporin4(f)andGFAP(g)isassociated
with focal demyelination (Luxol fast blue staining e) and deposition of
complement C9neo antigen (h). T-cell-mediated EAE with co-transfer
of control immunoglobulin. There is nodemyelination (Luxol fast blue
staining i), no loss of aquaporin 4 (j) GFAP (k)o ra-dystroglycan (l).
T-cell-mediated EAE with co-transfer of human immunoglobulin
containing aquaporin 4 antibody, 24 h after antibody transfer.
m Connexin 43 immunoreactivity is lost in areas of aquaporin 4 loss
(see Fig. 1b). n Staining for collagen IV shows some splitting of
basement membranes in inﬂamed vessels. T-cell-mediated EAE with
co-transfer of control immunoglobulin; no loss of connexin 43 is seen
(o); staining for collagen IV shows some splitting of basement
membranes in inﬂamed vessels (p). T-cell-mediated EAE with co-
transfer of anti-MOG antibodies. There is perivascular demyelination
(luxolfastbluestainingq),butnochangeinaquaporin4expression(r),
and no GFAP loss (s). However, connexin 43 immunoreactivity is
profoundly reduced within the lesion in comparison with the adjacent
normal white matter (t). The insert shows the punctate connexin 43
reactivity associated with the surface of glial cells (right), which is lost
in the lesion (left). Bar 100 lm
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123Similarly, earliest signs of demyelination and nuclear
changes of oligodendrocytes, resembling apoptosis were
seen at day 5 and the size of demyelinated lesions increased
thereafter, reaching a peak 12 days after LPS injection
(Fig. 2e, i).
Loss of AQP-4 is associated with structural disturbance
of the glia limitans
AQP-4 is concentrated in astrocytic foot processes at the
glia limitans and loss of AQP-4 in experimental NMO
lesions occurs concurrently with a retraction or destruction
of perivascular astrocytic foot processes at the glia limi-
tans. To analyze whether this is also the case after LPS
injection, we used two markers which allow analysis of the
structural organization of the glia limitans: ADG and col
IV. In the LPS lesions ADG reactive glial end feet were
lost in parallel with the loss of AQP-4 (Figs. 2h, i, 3e–l).
Col IV is present in the basement membranes of cerebral
endothelial cells and glial end feet, but no col IV is seen in
the extracellular space of the CNS parenchyma (Fig. 2n).
Damage of the perivascular glia limitans in LPS lesions,
however, resulted in the presence of col IV in the extra-
cellular matrix of the spinal cord tissue, which was
accentuated around the cell bodies of reactive astrocytes
(Figs. 2v–x, 3v–x). Furthermore, col IV immunoreactivity
was also seen within the cytoplasm of astrocytes,
suggesting its synthesis within the cells (Fig. 3w, x). No
alterations of ADG or col IV expression were seen in
control animals injected with saline (Figs. 2d, u, 3i, u).
Molecules which metabolically connect astrocytes
with oligodendrocytes are lost in lesions with both,
primary astrocyte or oligodendrocyte damage
Because demyelination in the LPS and the NMO model
follows astrocyte dysfunction, we analyzed additional
astrocytic molecules which play a role in oligodendrocyte
homeostasis. Oligodendrocytes in the CNS are linked to
astrocytes by heterotypic gap junctions composed of
connexin 32 (Cx32) and connexin 47 (Cx47) in oligo-
dendrocytes, and of connexin 30 (Cx30) and connexin 43
(Cx43) in astrocytes, with Cx32/Cx30 and Cx47/Cx43 as
coupling partners [22, 30]. These gap junctions allow the
trafﬁcking of metabolites and ions between astrocytes and
oligodendrocytes [3, 36]. The expression of both Cx30
and Cx43 was profoundly reduced in both, the LPS
lesions (Fig. 3m–t) as well as the experimental NMO
lesions (Fig. 1m). The time course of loss of Cx 43 and
30 in the LPS model closely followed that described
above for AQP-4. Interestingly, however, a similar loss of
Cx 30 and 43 immunoreactivity was also seen in primary
demyelinating lesions induced by anti-MOG antibodies
(Fig. 1t).
Table 3 Characterization of experimental inﬂammatory lesions
Demyelination
(mm
-2)
AQP-4 loss
(mm
-2)
GFAP loss
(mm
-2)
C9neo deposition
(mm
-2)
Extracellular Col IV
deposition (mm
-2)
No. of split blood
vessels (mm
-2)
LPS time course
LPSd0 0 0 0 - 00
LPSd1 0 0.06 ± 0.01 0 - 00
LPSd3 0 0.05 ± 0.01 0 - 0 0.5 ± 0.3
LPSd5 0.06 ± 0.02 0.12 ± 0.02 0.023 ± 0.01 - 0.01 ± 0.01 1.3 ± 0.8
LPSd8 0.16 ± 0.02 0.2 ± 0.02 0.07 ± 0.01 - 0.06 ± 0.01 2.8 ± 0.5
LPSd12 0.51 ± 0.02 0.24 ± 0.02 0.15 ± 0.02 - 0.11 ± 0.01 7.5 ± 1.8
LPSd15 0.29 ± 0.01 0.33 ± 0.01 0.16 ± 0.02 - 0.15 ± 0.01 9.8 ± 3.8
Saline 0 0 0 - 00
EAE time course
EAEd0 0 0 0 - 00
EAEd3 0 0 0 - 0 0.43 ± 0.3
EAEd6 0 0 0 - 0 6.6 ± 1
EAEd9 0 0 0 - 0 5.14 ± 0.6
EAEd12 0 0 0 - 0 1.9 ± 0.5
EAEd15 0 0 0 - 0 0.14 ± 0.1
EAE ? MOG (d1) 0.09 ± 0.03 0 0 ??? 00
EAE ? NMO (d1) 0.028 ± 0.005 0.57 ± 0.11 0.25 ± 0.1 ??? 00
EAE ? C Ig (d1) 0 0 0 - 00
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123Microglia cells are the primary target of LPS
LPS is recognized by toll-like receptor 4 (TLR4), which
acts in concert with the cluster of differentiation 14 (CD14)
protein. Astrocytes in vivo express none of these molecules
[9]. However, in marked contrast, microglia cells in vivo
readily express both TLR4 and CD14 [32]. Therefore, the
LPS effects on astrocytes following injections into the
dorsal funiculus seemed to be driven by microglia-derived
factors. In a next set of experiments, we therefore co-cul-
tured astrocytes with microglial cells with and without LPS
treatment, and analyzed astrocytic changes in morphology
and AQP-4 expression. Normally, the astrocyte cultures
were a mixture of both protoplasmic and stellate cells
(Fig. 4a, e). AQP-4 expression was very weak on the
stellate cells, and much stronger on the protoplasmic
astrocytes. In both cases, AQP-4 reactivity was uniformly
distributed over the cell membrane of astrocytes, with some
accentuation on membrane rufﬂes (Fig. 4i, m, q). This
picture did not change following the exposure of enriched
astrocyte cultures for 24 h with LPS (Fig. 4j, n, r).
However, upon co-culture with microglial cells, many
astrocytes acquired a reactive phenotype characterized by
the retraction of cell processes (Fig. 4c, g). Stellate astro-
cytes were less frequently observed, and the number of
astrocytes with a rounded-up appearance increased.
Although AQP-4 reactivity was still distributed over the
entire astrocytic cell surface, an aggregation of AQP-4
molecules was readily detectable, which was strongly
suggestive for internalization of AQP-4 by endocytosis
(Fig. 4k, o, s) [17]. The effect of microglial cells on
astrocytes in vitro can readily be explained, since these
microglia have an activated phenotype, even in the absence
of additional stimuli. However, when LPS was added to the
microglia–astrocyte co-cultures, the changes in astrocyte
morphology and AQP-4 reactivity became more pro-
nounced: stellate astrocytes were almost completely absent
from the cultures, the numbers of reactive and rounded-up
astrocytes increased (Fig. 4d, h), and aggregates of AQP-4
reactivity were more frequently detected (Fig. 4p, t).
Fig. 2 Astrocyte pathology and
demyelination in LPS-induced
spinal cord lesions: a–d no
pathological alterations of
astrocytes and no demyelination
are seen in animals injected with
saline into the spinal cord white
matter. 3 days after injection of
LPS, there is no demyelination
(Luxol fast blue staining e);
staining for aquaporin 4 is
reduced (f), but astrocytes are
still preserved (g). In contrast,
there is a profound loss of
a-dystroglycan reactivity at the
vascular glia limitans (h). At
day 12 after LPS injection, a
focal plaque of demyelination is
visible (Luxol fast blue staining
(i), associated with complete
loss of aquaporin 4 (j) and
a-dystroglycan reactivity (l) and
a profound reduction in
astrocytes and their processes
(k). Connexin 30
immunoreactivity is
progressively lost with time in
LPS lesions (n–p) in comparison
with saline-injected animals
(m). q–t Connexin 43
immunoreactivity shows similar
changes in comparison with that
for connexin 30. u–x LPS
lesions show an increasing
amount of collagen IV deposited
in the spinal cord extracellular
space with time. Bar 100 lm
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123Astrocyte pathology is seen in lesions of a subset of MS
patients with fulminant disease exacerbations
Having established that astrocyte dysfunction and damage
may be an important component in the pathogenesis of
inﬂammatory demyelinating lesions triggered by innate
immunity, we analyzed whether similar astrocytic changes
can also be seen in lesions of MS patients. We screened MS
autopsies, which included patients who died from acute
MS, or who had relapsing-remitting MS (patterns II and III
cases, Table 4 [24]), or secondary progressive or primary
progressive MS, and studied the lesions for evidence of
disturbance of the astrocytic glia limitans. To do so, we
used antibodies to AQP-4, ADG, col IV and GFAP. MS
lesions were classiﬁed as classical active lesions, slowly
expanding lesions or inactive lesions as described before
Fig. 3 Immunocytochemical
double staining for GFAP and
other markers visualized by
confocal laser microscopy. First
column normal white matter,
second column day 3 after LPS
injection, third column 12 days
after LPS injection, lesion edge,
fourth column 12 days after
LPS injection, lesion center.
In comparison with the control
white matter, there is a
progressive loss of astrocytes
and their processes with time
after LPS injection. In contrast
to the results shown in Fig. 2,
confocal microscopy reveals
more pronounced changes by
day 3 after LPS injection, due to
the very thin optical section
thickness and the much higher
resolution of this technique.
Note that in w and x most of the
remaining astrocytes show
collagen 4 immunoreactivity
within their cytoplasm (yellow
color), suggesting synthesis of
this antigen within astrocytes.
a–e, g–j, n–p, u–x Bar 25 lm.
f, k, l, m, q–t Bar 10 lm
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123[12]. In the majority of MS lesions, regardless of activity or
disease stage, we did not see evidence for a disruption of
the perivascular glia limitans (Fig. 5h–m). Only in a subset
of active lesions mainly following pattern III demyelina-
tion [24], which were present in patients with acute MS or
fulminant attacks of chronic MS, loss of perivascular
astrocytic foot processes was associated with col IV
depositionin the parenchymal extracellularspace (Fig. 5a–g).
Furthermore, col IV expression was also seen within the
cytoplasm of highly reactive astrocytes, and deposition of
Fig. 4 Consequences of co-culture with activated microglial cells on
the morphology of, and the expression of aquaporin 4 in, astrocytes in
vitro. a–h Changes in morphology, as revealed by GFAP immuno-
reactivity (green). Astrocyte cultures incubated without microglial
cells in the absence of LPS (a higher magniﬁcation in e) and in the
presence of 100 ng/ml LPS (b higher magniﬁcation in f) contain
protoplasmic and stellate astrocytes. Upon incubation with microglial
cells, the numbers of astrocytes with large cellular processes
decreases and the astrocytes start to round up (c higher magniﬁcation
in g). This process is even more pronounced upon incubation of
astrocytes with microglial cells in the presence of 100 ng/ml LPS
(d higher magniﬁcation in h). i–t Changes in aquaporin 4 expression.
The astrocytes were double stained with GFAP (green i–l, overlay
q–t) and AQP-4 (red m–p, overlay q–t). Astrocytes cultured without
microglial cells, both in the absence (i, m, q) or presence of 100 ng/
ml LPS (j, n, r), reveal a uniform, punctate staining pattern of AQP-4,
which is accentuated at membrane rufﬂes and cellular processes.
Astrocytes cultured in the presence of microglial cells (k, o, s) also
show punctate AQP-4 immunoreactivity on the cell surface. However,
in addition to this, a large number of astrocytes also show vesicle-like
AQP-4 aggregates. This is also seen in astrocytes cultured with
microglia cells in the presence of 100 ng/ml LPS (l, p, t). The data
shown are representative of two independently performed experi-
ments. Bar 100 lm
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123precipitated col IV was present on the extracellular surface
of reactive astrocyte cell bodies and processes, together
with massive surface expression of AQP-4 (Fig. 5d, f, g).
Split basement membranes, reﬂecting the widening of the
perivascular space due to inﬂammation, were seen in
similar extent in active lesions following pattern II and III
demyelination (Table 4).
Discussion
Our current study shows that astrocyte dysfunction pre-
cedes demyelination in two experimental models of
inﬂammatory demyelination with fundamentally different
pathogenesis. In NMO lesions speciﬁc autoantibodies tar-
get the astrocytic membrane protein AQP-4 and destroy
astrocytes through either activated complement, through a
mechanism of antibody-dependent cellular cytotoxicity, or
a mixture of both mechanisms [6, 7]. In the LPS model,
autoantibodies against AQP-4 do not play a role. Autoan-
tibodies against AQP-4 have not been seen in normal rats
[7] and the time between LPS injection and the appearance
of AQP-4 loss within the lesions (1 day) is too short for the
induction of an autoantibody response. Furthermore, we
did not ﬁnd immunoglobulin and complement deposition in
the lesions. In contrast, we saw that supernatants of LPS-
activated microglia can induce astrocyte dystrophy in vitro.
It has been described that LPS-activated microglial cells
produce a large number of molecules, among them inter-
leukin-1, tumor necrosis factor-alpha, and nitric oxide,
which can impair astrocyte function in vitro [33]. Despite
the completely different modes of the induction of astro-
cyte dystrophy, the consequences for astrocyte function
and lesion formation in vivo are essentially similar. In both
conditions, astrocytic foot processes at the perivascular glia
limitans are ﬁrst and most severely affected. This is
reﬂected by the loss of ADG, which is an important anchor
protein, linking the astrocyte processes with the molecules
of the extracellular matrix of the perivascular space, and
which is also involved in AQP-4 clustering at the glia
limitans. It is well established that ADG is selectively
cleaved at the parenchymal basement membrane at sites of
leukocyte extravasation in EAE [2]. However, in simple
EAE models, this cleavage does not seem to translate to a
complete loss of ADG reactivity in the lesions. Col IV, too,
is at least in part a marker for the intactness of the peri-
vascular glia limitans. It is also produced by astrocytes and
under normal conditions deposited in a polarized manner
on the astrocytic surface of the glia limitans. We show here
that col IV is expressed in the cytoplasm of reactive
astrocytes and excreted into the parenchymal extracellular
space of the CNS tissue, when the structure of the glia
limitans is impaired. In addition, it decorates the surface of
reactive astrocytes within the lesions, which may further
disturb astrocyte function.
The time course of events seen in our experiments suggests
that in both the NMO and the LPS lesions demyelination may
be a secondary consequence of astrocytic dysfunction. This
may reﬂect several different underlying mechanisms. Astro-
cyte dysfunction may impair blood–brain barrier function,
leading to perivascular precipitation of ﬁbrin. Precipitated
ﬁbrinispresentattheonsetofdemyelinationintheLPSlesions
[26] and is known to be an additional trigger for microglia
activation in inﬂammatoryconditions [1].Inaddition,we have
testedthe expressionofmolecules thatmayinpart be involved
in oligodendrocyte injury. The Cx30 and Cx43 form hetero-
meric gap junctions between astrocytes and oligodendrocytes
[30], and are thought to play a vital role for the delivery,
removal and general ﬂow of ions, osmotic water and metabo-
lites that sustain the normal functioning of oligodendrocytes
[16]. When this connection is interrupted, oligodendrocytes
may undergo a state of energy deprivation. A previously
reportedalternative candidate for oligodendrocyte injury is the
excitatory amino acid transporter EAAT2 [38 15]. It is
expressed in astrocytes and it is involved in the clearance of
glutamate from the extracellular space and, thus, it contributes
to extracellular glutamate homeostasis. Because oligodendro-
cytes are sensitive to glutamate receptor-mediated injury [27],
Table 4 Characterization of MS lesions
MS P III MS P II PGR MS
Demyelination ??? ??? ???
AQP-4 loss ??? (Patchy) --
Disturbed glia limitans ??? ± -
Diffuse reactivity of col IV in and on astrocytes ??? - -
No. of col IV positive astrocytes (mm
-2) 1.55 ± 0.7 0.09 ± 0.03 0.06 ± 0.02
Extracellular col IV deposition ??? ? ??
No. of split BV (mm
-2) 1.72 ± 0.1 1.6 ± 0.1 0.1 ± 0.02
MS P III MS lesions with pattern III demyelination, MS P II MS lesions with pattern II demyelination, PRG MS slowly expanding lesions of
progressive MS, col IV collagen IV, split BV vessels with split basement membranes
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123decreasedextracellularglutamatebufferingmaybeinvolvedin
oligodendrocyte degeneration and demyelination. It has been
concluded previously from in vitro data that this mechanism
may be important for the pathogenesis of demyelination in
NMO.
The link between astrocyte injury and demyelination has
also been observed in earlier studies. For example, ablation
of astrocytes lead to severe demyelination and neuronal as
well as oligodendrocyte death after spinal cord injury [10],
and to an increased spread of inﬂammation and tissue
damage in EAE [37]. Similar results were obtained when
signal transducer and activator of transcription 3 (STAT3)-
positive astrocytes were selectively killed [14]. Moreover,
depletion of GFAP-positive astrocytes after forebrain stab
injury lead to substantial neuronal degeneration that could
be attenuated by chronic glutamate receptor blockade [8];
and ﬁnally, a primary loss of astrocytes followed by
extensive demyelination was also observed after injection
of human complement and NMO IgG into the murine
cerebrum [35].
Although the profound structural impairment of astro-
cytes is well documented in the lesions of patients with
Fig. 5 Astrocyte pathology in multiple sclerosis lesions: a–g Ful-
minant active lesions of acute multiple sclerosis following pattern III
demyelination [21]. Myelin staining reveals an initial lesion (I) with
myelin pallor and a more advanced lesion with complete demyelin-
ation (DM a). In the area of the initial lesion, there are already
macrophages with myelin degradation products within their cyto-
plasm (b). Within the lesion, there is abundant expression of GFAP,
but the perivascular glia limitans is disrupted (c). Staining for
aquaporin 4 shows patchy loss of immunoreactivity with numerous
highly reactive protoplasmatic astrocytes with intense aquaporin 4
immunoreactivity on their surface (d insert). a-Dystroglycan immu-
noreactivity is only present on the glia limitans of some vessels and
there the intensity of expression is uneven and weak (e). Collagen IV
immunoreactivity is seen within the cytoplasm of reactive astrocytes,
which have lost their processes forming the glia limitans (f, g). In
addition, there is profound precipitation of collagen IV on the surface
of reactive astrocytes (g). h–n Astrocytes in a chronic expanding
lesion following pattern II demyelination [24]. Edge of an active
lesion with a broad rim of macrophages with early myelin degradation
products (h, i). In these lesions, profound astrocytic gliosis is seen and
the glia limitans is still preserved in GFAP stained lesions (j).
Aquaporin 4 is densely expressed on astrocytes between the
macrophages, containing myelin debris (k). a-Dystroglycan expres-
sion in the normal white matter (l) and within the lesion (m) shows
comparable expression patterns at the glia limitans. Collagen IV
staining shows profound splitting of the vascular basement mem-
branes within the lesions, but no immunoreactivity in astrocytes and
no collagen deposition within the parenchyma (n). Bar 100 lm; f bar
50 lm
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123NMO, potential pathological alterations of astrocytes in
MS lesions have not received major attention. Reactive
protoplasmatic gliosis and ﬁbrillar gliosis have been well
described in active and chronic MS lesions [19]. Here, we
show that at least in a subset of MS lesions astrocytic
changes are present which bear similarities to those in
NMO and LPS lesions. However, there is a major differ-
ence between MS and NMO lesions. In NMO lesions,
astrocytes are widely destroyed leading to large areas
devoid of astrocytes [28]. In contrast in MS astrocyte
pathology is mainly affecting the cell processes and
destruction or loss of astrocytes is minor. The functional
signiﬁcance of these changes is currently unknown, but in
analogy to NMO one may speculate that they too may be
involved in the pathogenesis of myelin and oligodendro-
cyte damage. Interestingly, those fulminant pattern III
lesions, where we predominantly found astrocyte dystro-
phy in our study, show a rather low extent of T-cell
inﬁltration [4, 13, 26] and in many respects are similar to
the lesions induced by focal LPS injection into the spinal
cord [11, 26]. It was thus suggested before that in these
lesions innate immunity may play a prominent pathoge-
netic role.
Finally, our current observations have consequences for
diagnostic neuropathology. Diagnosis of NMO is based on
the detection of circulating AQP-4 autoantibodies [20, 21].
However, there is a subset of patients, which is variable in
different cohorts and tests negative for AQP-4. We show
here an alternative mechanism of astrocytic injury and
AQP-4 loss, which does not depend on the presence of
AQP-4 autoantibodies. In addition, AQP-4 autoantibody
titers are frequently unavailable, when neuropathologists
are confronted with an autopsy or biopsy specimen with
suspected NMO. Currently, immunocytochemical detec-
tion of AQP-4 loss in the lesions is regarded as a very good
diagnostic marker for NMO lesions. In the light of our
current results, this assumption has to be qualiﬁed. AQP-4
loss can be seen in lesions with a completely different
immunopathogenesis than AQP-4 antibody-driven NMO.
However, in contrast to NMO lesions [28, 34], this AQP-4
loss is patchy and associated with profound overexpression
of this molecule on the cell surface of reactive astrocytes.
In addition, complete loss and destruction of astrocytes is
minor as compared to that seen in NMO lesions [25, 28,
34] and speciﬁc deposition of immunoglobulin and com-
plement at the site of astrocyte damage is absent.
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